Testicular cancer (TC) is the most frequent malignancy in men between 20 and 40 years of age, and the annual incidence rates are continuously increasing in the Western world.1 Since the introduction of cisplatin-based chemotherapy, at least 90% of the patients are cured,2 and testicular cancer survivors (TCSs) currently have a life expectancy similar to that of age-matched normal men, with posttreatment life spans of 30 to 50 years. Thus, an increasing number of TCSs experience survivorship problems related to the malignancy, its treatment, or both. © 2006 Springer Science+Business Media, Inc.
CITATION STYLE
Fosså, S. D., Travis, L. B., & Dahl, A. A. (2006). Medical and psychosocial issues in testicular cancer survivors. In Oncology: An Evidence-Based Approach (pp. 1825–1837). Springer New York. https://doi.org/10.1007/0-387-31056-8_104
Mendeley helps you to discover research relevant for your work.